These data are consistent with the results of the 2018 study by Z. Li et al., who demonstrated that myonectin concentrations in the blood serum of patients with newly diagnosed T2D and patients with impaired glucose tolerance (IGT) significantly exceeded those in healthy individuals. This evidence concerns the gene ERFE and Impaired glucose tolerance.